2023
Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study
Alamgeer M, Ling R, Ueno R, Sundararajan K, Sundar R, Pilcher D, Subramaniam A. Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. The Lancet Healthy Longevity 2023, 4: e675-e684. PMID: 38042160, DOI: 10.1016/s2666-7568(23)00209-x.Peer-Reviewed Original ResearchConceptsIntensive care unitRegistry-based cohort studyLong-term survivalAustralian intensive care unitsRetrospective registry-based cohort studyMetastatic cancerAssociated with shorter survival timeEffect of frailtyClinical Frailty ScaleShorter survival timeSurvival timeCohort studyAssociated with poor long-term survivalCare unitPoor long-term survivalIntensive care unit admissionTime-limited trialsCandidacy of patientsCox proportional hazards regression modelsRobust sandwich variance estimatorProportion of patientsProportional hazards regression modelsHazards regression modelsImpact of frailtyOverall survival
2015
The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer.
Soh I, Mogro M, Soo R, Pang A, Tan C, Chuah B, Zee Y, Wong A, Ow S, Sundar R, Lim J, Huang Y, Ling W, Yong W. The optimization of 5-fluorouracil (5FU) dose by pharmacokinetic (PK) monitoring in Asian patients with advanced-stage gastrointestinal (GI) cancer. Journal Of Clinical Oncology 2015, 33: 770-770. DOI: 10.1200/jco.2015.33.3_suppl.770.Peer-Reviewed Original ResearchTarget area-under-the-curveArea under the curveArea under the curve levelsAsian patientsDose adjustmentPK samplingPK sampling time pointsPK-guided dose adjustmentMedian area-under-the-curveGastrointestinal (GI) cancersRates of toxicityProportion of patientsHeterogeneous tumor typesSystemic plasma levelsBody surface areaCorrelation of response ratesG3/4 neutropeniaG3/4 toxicitiesTumor typesGI cancersPlasma levelsMFOLFOX6 regimenColorectal cancerGastric cancerPatients